Human cytomegalovirus gb polypeptide
AssigneePfizer Inc.
InventorsYuhang Liu, Ye Che, Xiaoyuan Sherry Chi, Philip Ralph Dormitzer, Jennifer Anne Nicki, Xiaojie Yao
Life of this patent
Estimating the term…
Abstract
The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least two introduced amino acid mutations relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.
Claims21
1-39. (canceled)
A glycoprotein B (gB) protein comprising at least one engineered disulfide mutation, wherein the gB protein comprises a cysteine mutation selected from the group consisting of:
- D217C, Y589C, M371C, W506C, N524C, and M684C, wherein the amino acid positions are numbered according to SEQ ID NO:
- 1.
A gB protein comprising an engineered disulfide mutation, wherein the gB protein comprises the following cysteine mutations:
- N524C and M684C, wherein the amino acid positions are numbered according to SEQ ID NO:
- 1.
A gB protein comprising engineered disulfide mutations, wherein the gB protein comprises each of the following cysteine mutations:
- D217C, Y589C, M371C, and W506C, wherein the amino acid positions are numbered according to SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.